Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Commercial

Strategy Explore this Topic

Set Alert for Strategy

Rani Therapeutics: ‘We’ve Tested A Dozen Molecules, All Of Them Have Worked’

In an exclusive interview with Generics Bulletin, Talat Imran, CEO of oral-dose biologics player Rani Therapeutics, talks adalimumab, partnering opportunities and financing, in the wake of kicking off pre-clinical development of its RT-111 proposed biosimilar to Janssen’s Stelara (ustekinumab) contained in its proprietary RaniPill Go ‘robotic’ capsule.

Biosimilars Value-Added Medicines

Hyloris Ramps Up Product Expansion With New Idiopathic Rhinitis Spray

Hyloris Pharmaceuticals’ new idiopathic rhinitis treatment sets it on track to achieve its target of around 30 portfolio assets by the end of 2024. 

Value-Added Medicines Strategy

Stada Begins Work On Romanian Hub

Stada has begun work on a facility in Romania into which the German giant is investing more than €50m to bolster the European supply chain.

Manufacturing Strategy
See All

Deals Explore this Topic

Set Alert for Deals

Biocon And Zentiva Sign Liraglutide Deal For 30 European Countries

Zentiva gains semi-exclusive commercialization rights to Biocon’s liraglutide drug-device combination in 30 countries, following a string of similar deals for the company since its 2018 acquisition.

Deals Diabetic Care

Lupin Turns Up Heat With Bausch Brands Acquisition, Perforomist Generic Launch

Two acquisitions of brands in as many months, Lupin has stepped up its game in the Americas. A buyout of nine established Bausch Health brands follows rights to two from Sunovion. While it awaits news on generic(g) Spiriva, the launch of gPerforomist will help expand Lupin’s respiratory franchise

Deals Generic Drugs

Teva To Advance Digihaler Data Ecosystem With Rimdi And HealthSnap

Teva’s new partnerships will make patient data from its digital inhalers more accessible to healthcare providers, potentially placing Teva’s asthma platform at the forefront of emerging treatment paradigms.

Value-Added Medicines Deals
See All

Manufacturing Explore this Topic

Set Alert for Manufacturing

Stada Begins Work On Romanian Hub

Stada has begun work on a facility in Romania into which the German giant is investing more than €50m to bolster the European supply chain.

Manufacturing Strategy

Alembic Straddles Oversupply And Shortages In US

One-off opportunities lift Alembic’s US generics business in the fiscal second quarter but the market continues to pose challenges amid surging oversupply and price erosion. On the other hand, a string of injectable approvals, including for ketorolac tromethamine, could open up opportunities for the company given the 'on and off' shortages.

Sales & Earnings Generic Drugs

Lannett Sees Boost From Adderall Shortages And Pricing Reprieve

In a busy period for Lannett, the company has benefited from a US shortage of generic Adderall rivals as well as a “more favorable pricing environment” to enjoy better results than expected – albeit with sales still significantly down on last year.

Sales & Earnings United States
See All

Sales & Earnings Explore this Topic

Set Alert for Sales & Earnings

Advanz Zeroes In On Innovative Assets And M&A

Advanz has identified three key spaces in which it is seeking to generate value: innovative assets, M&A and existing commercial infrastructure.

Value-Added Medicines M & A

Two Of Aurobindo’s Europe Biosimilar Filings Stuck

Even as two biosimilar filings in Europe are stuck due to a lack of inspection staff and a biosimilar could be approved in the UK without a Phase III trial, Aurobindo has licensed novel drug Ryzneuta from Yifan Pharma. Meanwhile, a $650m-$700m revenue forecast for the specialty business has been pushed back as both overall revenues and profits declined during Q2.

Biosimilars Strategy

Sun Pharma Reinforces Position As Indian Industry Leader

Sun Pharmaceuticals continues to dominate the Indian pharmaceutical space while its R&D costs are set to rise.

Sales & Earnings Research & Development

People Explore this Topic

Set Alert for People

Alvotech Switches CEO And Takes COO From Teva

Major leadership changes are being made at the top of Alvotech, with founder Robert Wessman stepping in to replace Mark Levick as CEO at the same time as Teva’s former head of global R&D, Hafrun Fridriksdottir, becomes COO of the biosimilars developer.

Executive Changes Leadership

Sanofi’s Jacqmin Joins Stada As Cron Departs

Stada has announced a change in management for its emerging markets division, with Sanofi’s Stéphane Jacqmin joining the firm from the start of 2023 to replace Carsten Cron, who is leaving the German generics and biosimilars giant for pastures new.

Executive Changes Leadership

Five Things Facing Teva’s New CEO Richard Francis

With Teva clearing up early who will replace outgoing president and CEO Kåre Schultz, Generics Bulletin looks at five issues that await his replacement, the former Sandoz head Richard Francis.

Biosimilars Generic Drugs
See All
UsernamePublicRestriction

Register